Chemistry:Robatumumab
From HandWiki
Short description: Chemical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD221 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6418H9960N1732O1992S42 |
| Molar mass | 144602.93 g·mol−1 |
  (what is this?) (verify) | |
Robatumumab (proposed INN; also known as SCH 717454 and MK-7454) is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor.[1]
Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete.[2][3] Merck has since discontinued development.[4]
References
- ↑ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines (2008). "Proposed International Nonproprietary Names: List 100". WHO Drug Information 22 (4): 311–67. https://www.who.int/medicines/publications/druginformation/innlists/PL100.pdf.
- ↑ "A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma". Pediatric Blood & Cancer 63 (10): 1761–70. October 2016. doi:10.1002/pbc.26087. PMID 27362300.
- ↑ Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
- ↑ "Robatumumab". Adis Insight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800027277.
 |  |
